NEXI vs. CPHI, KZIA, CING, DRUG, KTRA, TFFP, RNAZ, ARTL, SNPX, and GTBP
Should you be buying NexImmune stock or one of its competitors? The main competitors of NexImmune include China Pharma (CPHI), Kazia Therapeutics (KZIA), Cingulate (CING), Bright Minds Biosciences (DRUG), Kintara Therapeutics (KTRA), TFF Pharmaceuticals (TFFP), TransCode Therapeutics (RNAZ), Artelo Biosciences (ARTL), Synaptogenix (SNPX), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical preparations" industry.
China Pharma (NYSE:CPHI) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.
NexImmune received 22 more outperform votes than China Pharma when rated by MarketBeat users. Likewise, 61.11% of users gave NexImmune an outperform vote while only 0.00% of users gave China Pharma an outperform vote.
9.9% of NexImmune shares are owned by institutional investors. 46.0% of China Pharma shares are owned by company insiders. Comparatively, 19.4% of NexImmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, China Pharma and China Pharma both had 2 articles in the media. China Pharma's average media sentiment score of 0.00 beat NexImmune's score of -0.38 indicating that NexImmune is being referred to more favorably in the news media.
China Pharma has higher revenue and earnings than NexImmune.
China Pharma has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, NexImmune has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.
NexImmune has a net margin of 0.00% compared to NexImmune's net margin of -55.42%. NexImmune's return on equity of -54.31% beat China Pharma's return on equity.
Summary
NexImmune beats China Pharma on 6 of the 11 factors compared between the two stocks.
Get NexImmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NexImmune Competitors List
Related Companies and Tools
